Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 44 articles:
HTML format
Text format



Single Articles


    May 2018
  1. ZHANG J, Shao S, Han D, Xu Y, et al
    High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-kappaB signaling pathway.
    Int J Oncol. 2018 May 23. doi: 10.3892/ijo.2018.4420.
    PubMed     Text format     Abstract available


  2. OAK C, Khalifa AO, Isali I, Bhaskaran N, et al
    Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest.
    Int J Oncol. 2018 May 16. doi: 10.3892/ijo.2018.4407.
    PubMed     Text format     Abstract available


    April 2018
  3. QI Y, Zhao W, Li M, Shao M, et al
    High C-X-C motif chemokine 5 expression is associated with malignant phenotypes of prostate cancer cells via autocrine and paracrine pathways.
    Int J Oncol. 2018 Apr 30. doi: 10.3892/ijo.2018.4388.
    PubMed     Text format     Abstract available


  4. CHENG L, Zang J, Dai HJ, Li F, et al
    Ubiquitin ligase CHIP functions as an oncogene and activates the AKT signaling pathway in prostate cancer.
    Int J Oncol. 2018 Apr 24. doi: 10.3892/ijo.2018.4377.
    PubMed     Text format     Abstract available


  5. LUO Y, Li M, Zuo X, Basourakos SP, et al
    betacatenin nuclear translocation induced by HIF1alpha overexpression leads to the radioresistance of prostate cancer.
    Int J Oncol. 2018 Apr 12. doi: 10.3892/ijo.2018.4368.
    PubMed     Text format     Abstract available


  6. DU Z, Li L, Sun W, Wang X, et al
    HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a gamma-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzaluta
    Int J Oncol. 2018 Apr 12. doi: 10.3892/ijo.2018.4370.
    PubMed     Text format     Abstract available


    November 2017
  7. CHEN S, Nimick M, Cridge AG, Hawkins BC, et al
    Anticancer potential of novel curcumin analogs towards castrate-resistant prostate cancer.
    Int J Oncol. 2017 Nov 20. doi: 10.3892/ijo.2017.4207.
    PubMed     Text format     Abstract available


  8. EDWARDS DR, Moroz K, Zhang H, Mulholland D, et al
    PRL3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients.
    Int J Oncol. 2017 Nov 20. doi: 10.3892/ijo.2017.4208.
    PubMed     Text format     Abstract available


  9. XU W, Foster BA, Richards M, Bondioli KR, et al
    Characterization of prostate cancer cell progression in zebrafish xenograft model.
    Int J Oncol. 2017 Nov 6. doi: 10.3892/ijo.2017.4189.
    PubMed     Text format     Abstract available


    August 2017
  10. LU L, Li K, Mao YH, Qu H, et al
    Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo.
    Int J Oncol. 2017 Aug 10. doi: 10.3892/ijo.2017.4095.
    PubMed     Text format     Abstract available


    June 2017
  11. CHEN W, Liu Y, Chen H, Ning H, et al
    Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis.
    Int J Oncol. 2017 Jun 12. doi: 10.3892/ijo.2017.4038.
    PubMed     Text format     Abstract available


    May 2017
  12. BILIR B, Sharma NV, Lee J, Hammarstrom B, et al
    Effects of genistein supplementation on genomewide DNA methylation and gene expression in patients with localized prostate cancer.
    Int J Oncol. 2017 May 24. doi: 10.3892/ijo.2017.4017.
    PubMed     Text format     Abstract available


  13. OKATO A, Arai T, Kojima S, Koshizuka K, et al
    Dual strands of pre-miR150 (miR1505p and miR1503p) act as antitumor miRNAs targeting SPOCK1 in naive and castration-resistant prostate cancer.
    Int J Oncol. 2017 May 17. doi: 10.3892/ijo.2017.4008.
    PubMed     Text format     Abstract available


    April 2017
  14. LU S, Dong Z
    Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
    Int J Oncol. 2017 Apr 19. doi: 10.3892/ijo.2017.3964.
    PubMed     Text format     Abstract available


    March 2017
  15. QIAN B, Yao Y, Liu C, Zhang J, et al
    SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.
    Int J Oncol. 2017 Mar 22. doi: 10.3892/ijo.2017.3926.
    PubMed     Text format     Abstract available


    February 2017
  16. LI W, Li Y, Li G, Zhou Z, et al
    Ectopic expression of the ATP synthase beta subunit on the membrane of PC-3M cells supports its potential role in prostate cancer metastasis.
    Int J Oncol. 2017 Feb 16. doi: 10.3892/ijo.2017.3878.
    PubMed     Text format     Abstract available


  17. WORST TS, Meyer Y, Gottschalt M, Weis CA, et al
    RAB27A, RAB27B and VPS36 are downregulated in advanced prostate cancer and show functional relevance in prostate cancer cells.
    Int J Oncol. 2017 Feb 10. doi: 10.3892/ijo.2017.3872.
    PubMed     Text format     Abstract available


  18. HUANG Y, Tao T, Liu C, Guan H, et al
    Upregulation of miR-146a by YY1 depletion correlates with delayed progression of prostate cancer.
    Int J Oncol. 2017;50:421-431.
    PubMed     Text format     Abstract available


    December 2016
  19. HUANG H, Du T, Xu G, Lai Y, et al
    Matrine suppresses invasion of castration-resistant prostate cancer cells by downregulating MMP-2/9 via NF-kappaB signaling pathway.
    Int J Oncol. 2016 Dec 14. doi: 10.3892/ijo.2016.3805.
    PubMed     Text format     Abstract available


  20. HARTING T, Stubbendorff M, Willenbrock S, Wagner S, et al
    The effect of dichloroacetate in canine prostate adenocarcinomas and transitional cell carcinomas in vitro.
    Int J Oncol. 2016;49:2341-2350.
    PubMed     Text format     Abstract available


    October 2016
  21. LI K, Mao Y, Lu L, Hu C, et al
    Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel.
    Int J Oncol. 2016;49:1679-85.
    PubMed     Text format     Abstract available


    September 2016
  22. PAN XW, Gan SS, Ye JQ, Fan YH, et al
    SMC1A promotes growth and migration of prostate cancer in vitro and in vivo.
    Int J Oncol. 2016 Sep 19. doi: 10.3892/ijo.2016.3697.
    PubMed     Text format     Abstract available


  23. YI X, Zhang J, Yan F, Lu Z, et al
    Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy.
    Int J Oncol. 2016 Sep 16. doi: 10.3892/ijo.2016.3693.
    PubMed     Text format     Abstract available


    August 2016
  24. KHURANA N, Talwar S, Chandra PK, Sharma P, et al
    Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
    Int J Oncol. 2016 Aug 2. doi: 10.3892/ijo.2016.3641.
    PubMed     Text format     Abstract available


    June 2016
  25. LI J, Yang X, Guan H, Mizokami A, et al
    Exosome-derived microRNAs contribute to prostate cancer chemoresistance.
    Int J Oncol. 2016 Jun 3. doi: 10.3892/ijo.2016.3560.
    PubMed     Text format     Abstract available


  26. WANG L, Fu P, Zhao Y, Wang G, et al
    Dissociation of NSC606985 induces atypical ER-stress and cell death in prostate cancer cells.
    Int J Oncol. 2016 Jun 2. doi: 10.3892/ijo.2016.3555.
    PubMed     Text format     Abstract available


    May 2016
  27. YIN B, Zhang M, Zeng Y, Li Y, et al
    [Corrigendum] Downregulation of cytokeratin 18 is associated with paclitaxelresistance and tumor aggressiveness in prostate cancer.
    Int J Oncol. 2016 May 30. doi: 10.3892/ijo.2016.3545.
    PubMed     Text format     Abstract available


  28. OKATO A, Goto Y, Kurozumi A, Kato M, et al
    Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer.
    Int J Oncol. 2016 May 16. doi: 10.3892/ijo.2016.3522.
    PubMed     Text format     Abstract available


  29. JI W, Chen J, Mi Y, Wang G, et al
    Platelet-activating factor receptor activation promotes prostate cancer cell growth, invasion and metastasis via ERK1/2 pathway.
    Int J Oncol. 2016 May 12. doi: 10.3892/ijo.2016.3519.
    PubMed     Text format     Abstract available


  30. MITRAN B, Varasteh Z, Selvaraju RK, Lindeberg G, et al
    Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Int J Oncol. 2016;48:2124-34.
    PubMed     Text format     Abstract available


    April 2016
  31. WANG J, Yi S, Zhou J, Zhang Y, et al
    The NF-kappaB subunit RelB regulates the migration and invasion abilities and the radio-sensitivity of prostate cancer cells.
    Int J Oncol. 2016 Apr 25. doi: 10.3892/ijo.2016.3500.
    PubMed     Text format     Abstract available


  32. MORO L, Arbini AA, Marra E, Greco M, et al
    [Corrigendum] Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2.
    Int J Oncol. 2016 Apr 14. doi: 10.3892/ijo.2016.3487.
    PubMed     Text format     Abstract available


  33. OGURA T, Tanaka Y, Tamaki H, Harada M, et al
    Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Int J Oncol. 2016 Apr 8. doi: 10.3892/ijo.2016.3482.
    PubMed     Text format     Abstract available


    March 2016
  34. DOMINSKA K, Ochedalski T, Kowalska K, Matysiak-Burzynska ZE, et al
    Interaction between angiotensin II and relaxin 2 in the progress of growth and spread of prostate cancer cells.
    Int J Oncol. 2016 Mar 24. doi: 10.3892/ijo.2016.3458.
    PubMed     Text format     Abstract available


  35. HU K, Tian Y, Du Y, Huang L, et al
    Atrazine promotes RM1 prostate cancer cell proliferation by activating STAT3 signaling.
    Int J Oncol. 2016 Mar 10. doi: 10.3892/ijo.2016.3433.
    PubMed     Text format     Abstract available


    February 2016
  36. YIN B, Zhang M, Zeng Y, Li Y, et al
    Downregulation of cytokeratin 18 is associated with paclitaxelresistance and tumor aggressiveness in prostate cancer.
    Int J Oncol. 2016 Feb 17. doi: 10.3892/ijo.2016.3396.
    PubMed     Text format     Abstract available


  37. ZHOU P, Ma L, Zhou J, Jiang M, et al
    miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells.
    Int J Oncol. 2016 Feb 15. doi: 10.3892/ijo.2016.3392.
    PubMed     Text format     Abstract available


  38. LI Q, Li Y, Wang Y, Cui Z, et al
    Quantitative proteomic study of human prostate cancer cells with different metastatic potentials.
    Int J Oncol. 2016 Feb 4. doi: 10.3892/ijo.2016.3378.
    PubMed     Text format     Abstract available


    January 2016
  39. LIANG YX, Lu JM, Mo RJ, He HC, et al
    E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer.
    Int J Oncol. 2016 Jan 29. doi: 10.3892/ijo.2016.3364.
    PubMed     Text format     Abstract available


  40. GU H, Liu T, Cai X, Tong Y, et al
    [Corrigendum] Upregulated LMO1 in prostate cancer acts as a novel coactivator of the androgen receptor.
    Int J Oncol. 2016 Jan 18. doi: 10.3892/ijo.2016.3344.
    PubMed     Text format     Abstract available


    November 2015
  41. GROSSEBRUMMEL H, Peter T, Mandelkow R, Weiss M, et al
    Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways.
    Int J Oncol. 2015 Nov 27. doi: 10.3892/ijo.2015.3274.
    PubMed     Text format     Abstract available


  42. WANG M, Ren D, Guo W, Huang S, et al
    N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells.
    Int J Oncol. 2015 Nov 26. doi: 10.3892/ijo.2015.3270.
    PubMed     Text format     Abstract available


  43. FUJIWARA J, Sowa Y, Horinaka M, Koyama M, et al
    [Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.
    Int J Oncol. 2015 Nov 25. doi: 10.3892/ijo.2015.3265.
    PubMed     Text format     Abstract available


    April 2015
  44. LI Y, Wu Y, Abbatiello TC, Wu WL, et al
    Slug contributes to cancer progression by direct regulation of ERalpha signaling pathway.
    Int J Oncol. 2015;46:1461-72.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: